贝瑞基因(000710) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥383,743,362.77, representing a year-on-year increase of 31.47%[8] - Net profit attributable to shareholders of the listed company was ¥93,108,949.06, up 34.63% compared to the same period last year[8] - The net profit after deducting non-recurring gains and losses reached ¥93,000,745.33, a 37.51% increase year-on-year[8] - Basic earnings per share for the reporting period were ¥0.2596, an increase of 27.69% compared to the same period last year[8] - The weighted average return on net assets was 5.32%, a decrease of 1.03% compared to the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,021,056,065.13, an increase of 11.88% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company amounted to ¥1,795,632,271.63, reflecting a growth of 16.86% year-on-year[8] - The total number of shareholders at the end of the reporting period was 15,711[12] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥85,275,979.85, showing a significant increase of 608.46%[8] - Cash received from sales increased by 39.54% year-on-year, driven by higher collections due to increased business volume[22] - Cash paid for purchasing goods and services increased by 65.79% year-on-year, reflecting higher material and labor costs due to business growth[22] Expenses - Operating costs increased by 38.50% year-on-year, attributed to higher material and labor costs due to increased business volume[17] - Income tax expenses increased by 125.22% year-on-year, reflecting higher tax provisions due to business growth[18] - R&D expenses increased by 111.68% year-on-year, as the company intensified investment in the full industry chain of genetic testing[22] Investments and Financing - The company plans to issue bonds not exceeding RMB 400 million to support the construction of the Gene Big Data Center project, which will help expand asset scale and optimize capital structure[24] - The company terminated the investment in US-based Baena Gene Co., which will not adversely affect its financial status or operating results[23] - The company reported a total of 10,000,000 in entrusted financial management from its own funds, with an outstanding balance of 10,000,000 and no overdue amounts[28] Compliance and Governance - There were no instances of non-compliance with external guarantees during the reporting period[31] - The company did not have any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[32] - There were no derivative investments during the reporting period[29] Other Information - The company reported non-recurring gains of ¥6,479,650.00 from government subsidies closely related to business operations[9] - Prepayments increased by 85.66% compared to the beginning of the year, mainly due to increased payments for engineering construction and equipment procurement[16] - Other receivables increased by 214.76% compared to the beginning of the year, primarily due to an increase in standby loan borrowings[16] - Inventory increased by 31.89% compared to the beginning of the year, driven by increased material procurement due to business growth[16] - The company conducted on-site research activities on August 22 and August 28, 2018, with institutional investors participating[30]